Jeffrey W. Albers Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Jeffrey W. Albers.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Jeffrey W. Albers. Jeffrey W. Albers is a CEO and President in Blueprint Medicines Corp ($BPMC) and a Director in Magenta Therapeutics, Inc. ($MGTA) and a Director in Kymera Therapeutics, Inc. ($KYMR).
Address: C/O BLUEPRINT MEDICINES CORPORATION, 215 FIRST STREET CAMBRIDGE 02142 MA
Companies in which Jeffrey W. Albers is an Insider
Blueprint Medicines Corp
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Jeffrey W. Albers: CEO and President
Holdings: 179,948 shares
Current Value: $6,449,336
Latest Transaction: May 14 2021
$BPMC Market Capitalization: $979.55M
$BPMC Previous Close: $35.84
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Kymera Therapeutics, Inc.
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of Jeffrey W. Albers: Director
Holdings: 0 shares
Latest Transaction: Aug 21 2020
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Magenta Therapeutics, Inc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Jeffrey W. Albers: Director
Holdings: 4,152 shares
Latest Transaction: Jun 09 2020
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Latest Insider Trading Transactions of Jeffrey W. Albers
Sentiment: All, BPMC, KYMR, MGTA
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 14 2021 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Option Exercise | M | 1.87 | 7,500 | 14,025 | 166,403 | |
| May 14 2021 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Option Exercise | M | 15.01 | 17,500 | 262,675 | 122,500 | |
| May 14 2021 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Sell | S | 91.89 | 2,953 | 271,351 | 172,448 | 175.4 K to 172.4 K (-1.68 %) |
| May 14 2021 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Sell | S | 92.62 | 16,383 | 1,517,393 | 175,401 | 191.8 K to 175.4 K (-8.54 %) |
| May 14 2021 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Sell | S | 93.33 | 5,664 | 528,621 | 191,784 | 197.4 K to 191.8 K (-2.87 %) |
| May 14 2021 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Buy | M | 15.01 | 17,500 | 262,675 | 197,448 | 179.9 K to 197.4 K (+9.73 %) |
| May 14 2021 | BPMC | Blueprint Medicine ... | Albers Jeffrey W. | CEO and President | Buy | M | 1.87 | 7,500 | 14,025 | 179,948 | 172.4 K to 179.9 K (+4.35 %) |